NewAmsterdam Pharma Company N.V.
Prognozy (mln)
| Okres |
2024-12-31 |
2025-12-31 |
2026-12-31 |
2027-12-31 |
2028-12-31 |
2029-12-31 |
| Przychód (średnia) |
33.77 |
18.78 |
30.16 |
137.85 |
318.91 |
644.06 |
| Przychód Δ r/r |
0.00% |
-44.39% |
60.60% |
357.06% |
131.34% |
101.96% |
| Przychód (min) |
14.56 |
2.92 |
4.69 |
21.43 |
49.58 |
100.13 |
| Przychód (max) |
39.99 |
53.25 |
85.52 |
390.89 |
904.27 |
1,826.23 |
| EBITDA (średnia) |
-0.23 |
-0.13 |
-0.21 |
-0.95 |
-2.20 |
-4.45 |
| EBIT (średnia) |
-0.23 |
-0.13 |
-0.21 |
-0.95 |
-2.21 |
-4.46 |
| EBIT % |
-0.69% |
-0.69% |
-0.69% |
-0.69% |
-0.69% |
-0.69% |
| Zysk netto (średni) |
-191.68 |
-166.96 |
-182.17 |
-139.11 |
-45.61 |
132.93 |
| Zysk netto % |
-567.56% |
-889.04% |
-604.00% |
-100.91% |
-14.30% |
20.64% |
| EPS (średnia) |
-2.03 |
-1.77 |
-1.93 |
-1.47 |
-0.48 |
1.41 |
| Liczba analityków (Przychody) |
10 |
13 |
13 |
6 |
8 |
12 |
| Liczba analityków (EPS) |
1 |
1 |
1 |
1 |
1 |
1 |
| symbol |
NAMSW |
NAMSW |
NAMSW |
NAMSW |
NAMSW |
NAMSW |